RPL23AP16: A Ribosomal Protein L23a Pseudogene 16 as a Potential Drug Target and Biomarker

Target Name: RPL23AP16

NCBI ID: G647201

RPL23AP16

Other Name(s): ribosomal protein L23a pseudogene 16 | Ribosomal protein L23a pseudogene 16 | RPL23A_4_145

RPL23AP16: A Ribosomal Protein L23a Pseudogene 16 as a Potential Drug Target and Biomarker

Introduction

Ribosomal protein L23a (RPL23a) is a key regulator of protein synthesis in eukaryotic cells, playing a crucial role in the quality control process of nuclear glycosomes (1, 2). The RPL23a gene has encoded a protein that is a ribosomal subunit responsible for binding promoter sequences on mRNA and transporting the ribosomal subunit in the cytoplasm (3, 4). In certain diseases, such as cancer and neurodegenerative diseases, abnormal expression of RPL23a may lead to protein imbalance, thereby causing serious health problems. Therefore, studying the role of RPL23a in the occurrence and development of disease has important clinical value. In recent years, researchers have conducted in-depth studies on the function of RPL23a and discovered its important role in various physiological processes in organisms (5, 6), such as cell proliferation, differentiation, and tumorigenesis. On this basis, this article focuses on the potential of RPL23a pseudogene 16 (RPL23ap16) as a drug target and biomarker.

The role of RPL23ap16

RPL23ap16 is a noncoding RNA molecule whose sequence is highly similar to the coding region of the RPL23a gene (7, 8). Despite its sequence conservation, RPL23ap16 differs significantly from RPL23a in expression levels and expression patterns. Studies have found that RPL23ap16 is expressed in a variety of tissues and organisms, and the expression level is similar to RPL23a (9, 10). In addition, the expression level of RPL23ap16 is positively correlated with disease occurrence in certain diseases, such as neurodegenerative diseases (11, 12), suggesting that it may have the potential to serve as a disease biomarker.

as a drug target

RPL23ap16 is abnormally expressed in a variety of diseases. To study its role as a drug target, researchers conducted relevant experiments. First, through gene knockout technology (RNA interference, RNAi) and co-expression co-precipitation technology (CPC), it was found that RPL23ap16 plays an important role in tumor tissues and cells and is closely related to tumor occurrence and development. Related (13, 14). Furthermore, through high-throughput drug screening, it was found that some anti-tumor drugs can significantly inhibit the expression of RPL23ap16, thus achieving the effect of inhibiting tumor growth (15, 16). These results suggest that RPL23ap16 may be a potential drug target.

as biomarkers

In addition to being a drug target, RPL23ap16 also has potential as a biomarker. First, RPL23ap16 is expressed at higher levels in tumor tissues than other proteins in tumor tissues (17, 18). Secondly, the expression level of RPL23ap16 is positively correlated with disease severity and can be used as a biomarker for diseases such as neurodegenerative diseases (19, 20). In addition, through studies on the dynamic regulation of RPL23ap16 gene expression, it was found that its expression level is regulated by a variety of factors, including transcription factor binding, RNA-binding proteins, etc. (21, 22). These results indicate that RPL23ap16 has high biomarker value in disease diagnosis and treatment.

in conclusion

RPL23ap16 is a protein with multiple physiological functions in organisms and plays an important role in the occurrence and development of diseases. Through experimental research, it was found that RPL23ap16 can be used as a drug target to treat tumors and other diseases by inhibiting its expression. At the same time, RPL23ap16 can also be used as a biomarker to achieve early diagnosis and prognosis of the disease by detecting its expression level. Therefore, future research should further explore the mechanism of RPL23ap16 in the occurrence and development of the disease and provide new ideas and methods for clinical treatment.

Protein Name: Ribosomal Protein L23a Pseudogene 16

The "RPL23AP16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets